Is Aripiprazole an Effective Adjunct to Reduce Metabolic Adverse Effects Caused by Clozapine in Patients With Schizophrenia-A Systematic Review.

Neuropsychopharmacol RepSep 1, 2026
Clinical ResearchPsychiatryOpen access

Avtaar Singh, Soban Sadiq

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the effectiveness of adjunctive Aripiprazole in reducing metabolic adverse effects from Clozapine in patients with schizophrenia. Eight studies were included, revealing that Aripiprazole may improve LDL and total cholesterol levels and reduce body weight. However, changes in fasting glucose and waist circumference were inconsistent.

Key findings

  • Adjunctive Aripiprazole improved LDL and total cholesterol levels in several studies.
  • Body weight reductions were observed with adjunctive Aripiprazole.
  • Fasting glucose levels showed limited or inconsistent changes.
  • The overall evidence is limited, particularly regarding high-quality, long-term trials.

Why it matters

Understanding the potential benefits of adjunctive therapies like Aripiprazole is crucial for managing the metabolic side effects associated with Clozapine, which can significantly impact patient health and treatment adherence.

What to keep in mind

The review highlights variability in outcomes, study design, and patient characteristics, indicating a need for further research.

Source

PubMed · PMID 42521648Free full text on PubMed Central

Published in Neuropsychopharmacol Rep. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.